Timothy J Inocencio

4PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 20, 2026
Comparative economic analysis of B-cell maturation antigen-targeted bispecific antibodies in triple-class exposed relapsed/refractory multiple myeloma: linvoseltamab versus teclistamab and elranatamab.

|Feb 27, 2025
Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.

Sikander Ailawadhi, Timothy J Inocencio, Carol Mansfield

|May 25, 2022
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.

Sepehr Farahbakhshian, Timothy J Inocencio, Gregory Poorman

|Feb 26, 2021
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.

Claire L Simons, Daniel Malone, Michael Wang

Pageof 1

Frequent Collaborators

2 joint publications

James Harnett

1 joint publications

Claire L Simons

1 joint publications

Daniel Malone

1 joint publications

Michael Wang